Benefits of rivastigmine on attention in dementia associated with Parkinson disease.
In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. Significant benefits of rivastigmine over placebo were seen on all aspects of attention assessed: sustained attention, focused attention, consistence of responding, and central processing speed.
Wesnes
K A
KA
Cognitive Drug Research, Goring-on-Thames, United Kingdom. keithw@cdr.org.uk
McKeith
I
I
Edgar
C
C
Emre
M
M
Lane
R
R
D000368:Aged; D000369:Aged, 80 and over; D001288:Attention / Q000187:drug effects* / Q000502:physiology; D003071:Cognition / Q000187:drug effects / Q000502:physiology; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D003342:Corpus Striatum / Q000187:drug effects / Q000503:physiopathology; D003704:Dementia / Q000188:drug therapy* / Q000209:etiology* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005625:Frontal Lobe / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009434:Neural Pathways / Q000187:drug effects / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications*; D048448:Phenylcarbamates / Q000008:administration & dosage*; D010919:Placebos; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D000068836:Rivastigmine; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D010919:Placebos; D000068836:Rivastigmine